Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navigating GU Oncology in a Male-Dominated Field

March 25, 2024
By Mary-Ellen Taplin, MD
News
Video

Mary-Ellen Taplin, MD, spoke about working in genitourinary oncology and how she has maneuvered the field as a woman.

Being a woman in the oncology field can sometimes be difficult. From managing work-life balance to being outnumbered among colleagues, it can take its toll. Mary-Ellen Taplin, MD, sat down for a discussion on Breaking Barriers: Women in Oncology to explain her journey and any challenges she experienced in her career.

Taplin, chair of the Executive Committee for Clinical Research and institute physician at Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School, recounted some of the experiences during her fellowship. However, she doesn’t believe those disparities or challenges would happen today, as the field has evolved.

She also touched on the number of genitourinary (GU) oncologists she works with at Dana-Farber, with the majority being women. However, other specialties, such as urology or radiation oncology, are having the opposite effect.

Transcript:

GU Oncology is a male-dominated field, especially on the urology side. When I started studying prostate cancer, let’s just say 1992, GU medical oncology was in its infancy. Most of the major cancer centers had very few practicing GU medical oncologists. Being a woman in GU medical oncology, there were very few of us but there were very few GU medical oncologists especially compared with today. I don’t perceive any significant barriers as a woman, especially on the medical oncology side. There are a lot of opportunities to work collaboratively, with people on different specialties, at least in the Boston area. We have a lot of women at Dana-Farber—maybe 7 or 8, GU medical oncologists that are women. But in the other specialties around us like urology and radiation oncology there are very few, if any, women who practice clinical prostate cancer in those areas. [I would say] medical oncology is more diverse.

The challenges that I’ve experienced were when I was a fellow. It was a long time ago, and medicine was very male dominated. For instance, out of 4 years of fellowship, with 12 [participants] only 2 were women and I had 1 child during my fellowship; the other woman had 2 children during the fellowship. It was talked about almost in front of us, that [our colleagues] were glad [more] women [didn’t match to] the fellowship. I don’t think that would happen today. Our society has become more inclusive and more welcoming to work-life balances, and some specific challenges around childbearing and rearing that women have.

Recent Videos
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Related Content
Advertisement

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

Roman Fabbricatore
May 21st 2025
Article

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.


Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.


Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Roman Fabbricatore
May 9th 2025
Article

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.


No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.

EVP Before Consolidative Surgery Optimizes Responses in Urothelial Cancer

Sabrina Serani
May 2nd 2025
Article

No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.

Related Content
Advertisement

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

Roman Fabbricatore
May 21st 2025
Article

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.


Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.


Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

Roman Fabbricatore
May 9th 2025
Article

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.


No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.

EVP Before Consolidative Surgery Optimizes Responses in Urothelial Cancer

Sabrina Serani
May 2nd 2025
Article

No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.